American Journal of Cardiology
Volume 103, Issue 9 , Pages 1269-1274 , 1 May 2009

Usefulness of Myeloperoxidase Levels in Healthy Elderly Subjects to Predict Risk of Developing Heart Failure

  • W.H. Wilson Tang, MD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-444-2121; fax: 216-445-6165
    • ,
  • Ronit Katz, DPhil

      Affiliations

    • Collaborative Health Studies Coordinating Center, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • ,
  • Marie-Luise Brennan, PhD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Ronnier J. Aviles, MD

      Affiliations

    • Overlake Internal Medicine Associates, Bellevue, Washington
    • ,
  • Russell P. Tracy, PhD

      Affiliations

    • Department of Pathology, University of Vermont College of Medicine, Colchester, Vermont
    • ,
  • Bruce M. Psaty, MD, PhD

      Affiliations

    • Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Department of Health Services, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington
    • Center for Health Studies, Group Health, Seattle, Washington
    • ,
  • Stanley L. Hazen, MD, PhD

      Affiliations

    • Department of Cell Biology, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio
    • Department of Cardiovascular Medicine, Center for Cardiovascular Diagnostics and Prevention, Cleveland Clinic, Cleveland, Ohio

Received 14 November 2008 ,Revised 13 January 2009 ,Accepted 13 January 2009.

References 

  1. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134–1139
  2. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524–37532
  3. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604
  4. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007;99:1364–1368
  5. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445
  6. Meuwese MC, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals; the EPIC-Norfolk prospective population study. J Am Coll Cardiol. 2007;50:159–165
  7. Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993–2000
  8. Tang WH, Brennan ML, Philip K, Tong W, Mann S, Van Lente F, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006;98:796–799
  9. Tang WH, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, et al. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol. 2007;49:2364–2370
  10. Askari AT, Brennan ML, Zhou X, Drinko J, Morehead A, Thomas JD, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615–624
  11. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1:263–276
  12. Psaty BM, Kuller LH, Bild D, Burke GL, Kittner SJ, Mittelmark M, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995;5:270–277
  13. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–1637
  14. Ives DG, Fitzpatrick AL, Bild DE, Psaty BM, Kuller LH, Crowley PM, et al. Surveillance and ascertainment of cardiovascular events (The Cardiovascular Health Study). Ann Epidemiol. 1995;5:278–285
  15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  16. Pearte CA, Furberg CD, O'Meara ES, Psaty BM, Kuller L, Powe NR, et al. Characteristics and baseline clinical predictors of future fatal versus nonfatal coronary heart disease events in older adults: the Cardiovascular Health Study. Circulation. 2006;113:2177–2185
  17. Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, et al. Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation. 2005;112:2812–2820
  18. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J. 2006;152:94–101
  19. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:1251–1257
  20. Vasan RS, Sullivan LM, D'Agostino RB, Roubenoff R, Harris T, Sawyer DB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139:642–648
  21. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  22. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, et al. C-Reactive protein and risk of heart failure (The Rotterdam Study). Am Heart J. 2006;152:514–520
  23. van Vark LC, Kardys I, Bleumink GS, Knetsch AM, Deckers JW, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam Study. Eur Heart J. 2006;27:2346–2352

 This work was supported by Grants No. P01 HL076491-055328, HL077107-050004, and P01 HL087018-020001 from the National Institutes of Health, Bethesda, Maryland, and contracts previously supporting development of the Cardiovascular Health Study, including N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, with additional contribution from the National Institute of Neurological Disorders and Stroke, Bethesda, Maryland. Drs. Hazen and Tang were supported by Grant No. 1UL1RR024989 from the National Institutes of Health. Dr. Tang reports having received research grant support and honorarium from Abbott Laboratories. Dr. Hazen is named as co-inventor on pending and issued patents filed by the Cleveland Clinic that relate to the use of biomarkers in inflammatory and cardiovascular disease; reports he is the scientific founder of PrognostiX Inc.; has received speaking honoraria from Pfizer, AstraZeneca, Merck, Merck Schering Plough, BioSite, Lilly, Wyeth, and Abbott; has received research grant support from Abbott Diagnostics, Pfizer, Merck, PrognostiX Inc., Hawaii Biotech, ArgiNOx, Sanofi, and Takeda; and has received consulting fees from Abbott Laboratories, Pfizer, PrognostiX Inc., Wyeth, BioPhysical, and AstraZeneca.

PII: S0002-9149(09)00120-9

doi: 10.1016/j.amjcard.2009.01.026

American Journal of Cardiology
Volume 103, Issue 9 , Pages 1269-1274 , 1 May 2009

Article Tools

* Image Usage & Resolution